However, biotech and health care naysayers have been awfully quiet in recent weeks. The iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB) and the SPDR S&P Biotech ETF (NYSEArca: XBI) gained 7.1% and 17.8%, respectively last month, but those that decried biotech’s valuations in February and March were nowhere to be found in May and June as the industry’s stocks and ETFs roared back. [The Biotech Rally No One Loves]
Some analysts and fund managers still see pockets of opportunity within the health care sector, including hospital stocks, CNBC reports. The SPDR S&P Health Care Services ETF (NYSEArca: XHS) is one ETF with which to play that trend.
XHS sports a higher P/E ratio than XLV, but the former touched a new all-time high today, cementing its status as one of the more credible Obamacare ETFs most investors have not heard of. Nearly a third of the ETF’s weight is allocated to health care facilities operators. XHS has more than tripled in size since mid-December 2013.
Health Care Select Sector SPDR
